BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  U.S. Surgitech Announces Contract Agreement with Vizient

  U.S. Surgitech Inc. has announced today that as of January 1, 2022 , they have been awarded a contract in the category of patient positioning with Vizient.

  January 31, 2022

   · 

  1 min read
• Biotech Beach

  Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan 31, 2022

  Cardiff Oncology, Inc. announced that on January 31, 2022, non-qualified stock option awards to purchase an aggregate of 55,008 shares of its common stock were granted to one new employee.

  January 31, 2022

   · 

  2 min read
• Biotech Beach

  ImmunityBio Announces Promising Clinical Study Results for ‘Kick and Kill’ HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy

  ImmunityBio, Inc., a clinical-stage immunotherapy company, announced promising study results that demonstrate the activation of CD4+ and CD8+ T cells and natural killer cells in people living with HIV by ImmunityBio’s IL-15 superagonist Anktiva.

  January 31, 2022

   · 

  9 min read